DK0734730T3 - Anvendelse af en CGRP-antagonist til behandling af øjen- eller øjenlågskløe og -dysæstesier - Google Patents

Anvendelse af en CGRP-antagonist til behandling af øjen- eller øjenlågskløe og -dysæstesier

Info

Publication number
DK0734730T3
DK0734730T3 DK96400459T DK96400459T DK0734730T3 DK 0734730 T3 DK0734730 T3 DK 0734730T3 DK 96400459 T DK96400459 T DK 96400459T DK 96400459 T DK96400459 T DK 96400459T DK 0734730 T3 DK0734730 T3 DK 0734730T3
Authority
DK
Denmark
Prior art keywords
eyelid
dysesthesia
itching
treat
cgrp antagonist
Prior art date
Application number
DK96400459T
Other languages
Danish (da)
English (en)
Inventor
Lacharriere Olivier De
Lionel Breton
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oreal filed Critical Oreal
Application granted granted Critical
Publication of DK0734730T3 publication Critical patent/DK0734730T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
DK96400459T 1995-03-28 1996-03-04 Anvendelse af en CGRP-antagonist til behandling af øjen- eller øjenlågskløe og -dysæstesier DK0734730T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9503629A FR2732222B1 (fr) 1995-03-28 1995-03-28 Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux

Publications (1)

Publication Number Publication Date
DK0734730T3 true DK0734730T3 (da) 2001-12-17

Family

ID=9477499

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96400459T DK0734730T3 (da) 1995-03-28 1996-03-04 Anvendelse af en CGRP-antagonist til behandling af øjen- eller øjenlågskløe og -dysæstesier

Country Status (15)

Country Link
US (2) US6169069B1 (de)
EP (1) EP0734730B1 (de)
JP (1) JP3024064B2 (de)
AR (1) AR002975A1 (de)
AT (1) ATE205089T1 (de)
BR (1) BR9601461A (de)
CA (1) CA2172779C (de)
DE (1) DE69614907T2 (de)
DK (1) DK0734730T3 (de)
ES (1) ES2163596T3 (de)
FR (1) FR2732222B1 (de)
HU (1) HUP9600766A3 (de)
MX (1) MX9601149A (de)
PL (1) PL313513A1 (de)
RU (1) RU2155601C2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US7112334B2 (en) * 2001-06-05 2006-09-26 Freiberg Roberta C Allergy inhibition
US20040038861A1 (en) * 2001-11-26 2004-02-26 Cooper Garth J. S. Methods and compositions for normalizing lipid levels in mammalian tissues
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
MY153249A (en) 2005-11-14 2015-01-29 Rinat Neuroscience Corp Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CA2716424C (en) * 2008-03-04 2015-04-28 Pfizer Limited Methods of treating chronic pain
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
KR20140048218A (ko) * 2011-06-28 2014-04-23 바이엘 헬스케어 엘엘씨 레고라페닙을 함유하는 국소 안과용 약학 조성물
US10143703B2 (en) 2014-01-02 2018-12-04 Massachusetts Eye And Ear Infirmary Treating ocular neovascularization
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
PE20161439A1 (es) 2014-03-21 2017-01-26 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE128359T1 (de) * 1988-01-11 1995-10-15 Amylin Pharmaceuticals Inc Behandlung von diabetes mellitus typ 2.
SE9201425D0 (sv) * 1992-05-06 1992-05-06 Kabi Pharmacia Ab Method and means for preventing constriction of the pupil in the eye

Also Published As

Publication number Publication date
ATE205089T1 (de) 2001-09-15
US6344438B1 (en) 2002-02-05
AR002975A1 (es) 1998-05-27
JP3024064B2 (ja) 2000-03-21
HUP9600766A3 (en) 1998-04-28
CA2172779C (fr) 2001-12-25
US6169069B1 (en) 2001-01-02
EP0734730B1 (de) 2001-09-05
EP0734730A1 (de) 1996-10-02
RU2155601C2 (ru) 2000-09-10
BR9601461A (pt) 1998-03-31
JPH08268913A (ja) 1996-10-15
ES2163596T3 (es) 2002-02-01
PL313513A1 (en) 1996-09-30
HU9600766D0 (en) 1996-05-28
DE69614907D1 (de) 2001-10-11
CA2172779A1 (fr) 1996-09-29
FR2732222B1 (fr) 1997-04-25
FR2732222A1 (fr) 1996-10-04
MX9601149A (es) 1997-08-30
DE69614907T2 (de) 2002-01-17
HUP9600766A2 (en) 1997-06-30

Similar Documents

Publication Publication Date Title
DK0734729T4 (da) Anvendelse af en CGRP-antagonist til behandling af hudrödme af neurogen oprindelse og den opnåede sammensætning
DK0734730T3 (da) Anvendelse af en CGRP-antagonist til behandling af øjen- eller øjenlågskløe og -dysæstesier
DK108997A (da) Fremstilling og krystalformer af 2-methylthien-benzodiazepin
KR960026600U (ko) 서랍 및 서랍의 조립방법
FR2661475B1 (fr) Combinaison de vilebrequin et de volant d'inertie.
FI932695A0 (fi) Angiotensin I kymas-inhibitorer inklusive humant hjaertkymas
LV11465A (lv) Heterocikliski amidini panemiens to iegusanai un pielietojums
PT744437E (pt) Misturas de compostos de organossilano e sua utilizacao
KR950701022A (ko) 부직포웹의 후처리 방법(Post-treatment of nonwoven webs)
FR2732220B1 (fr) Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
DE69620243D1 (de) Haupt- und nebenstromfilter
DE69124145D1 (de) Bauwerk und Aufbaumethode
DK0839033T3 (da) Anvendelse af L-carnitin og derivater til reducering af ceramidniveauer og potensering af antiretroviral virkning
FI934724A7 (fi) Kylbehaollare
KR970006691A (ko) 골재유실을 방지하는 방파제 축조공법 및 그 골재유실방지장치
NO924219D0 (no) Konstruksjon bestaaende av primaer- og sekundaerkonstruksjoner
KR920007957U (ko) 비탈면 수로 겸용 보호블럭
KR960008277U (ko) 슬라브개구부의 낙하방지구조
KR920021881U (ko) 최루분사용
SE9002524D0 (sv) Anordning vid svarvstaal
ITMI912161A0 (it) Riduzione degli inquinanti nell'effluente di combustione
SE9000411D0 (sv) Dusch- och badanordning
BR9102975A (pt) Conjunto de chuveiro portatil e chuveiro
KR920002719U (ko) 수로겸용 비탈면 보호블록
BA95039A (bs) Set za prevenciju i terapiju bolne menstruacije